Cameroon Mobile Phone SMS Trial

HIV Clinical Trial

— CAMPS  

Official title:

Improving Adherence to HAART Using Mobile Phone Text Messages

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01247181
• Other study ID #: CAMPS
• Secondary ID: PACTR20101100026
• Status: Completed
• Phase: N/A
• First received: November 22, 2010
• Last updated: September 7, 2011
• Start date: November 2010
• Est. completion date: July 2011

Study information

• Verified date: September 2011
• Source: Yaounde Central Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Cameroon: National Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The investigators hypothesize that sending weekly motivational text messages to people infected with HIV will encourage them to take their medication, compared to usual care.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: July 2011
• Est. primary completion date: July 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

• On HAART for at least 1 month

• 21 years or more

• Owns a mobile phone

• Can read text messages

Exclusion Criteria:

• On HAART for less than 1 month

• Aged less than 21 years

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Adherence
• HIV

Intervention

Other:
• Mobile phone text message
Weekly message with motivational content
• Usual care
Usual care provided at clinic

Locations

Country	Name	City	State
Cameroon	Yaounde Central Hospital Accredited Treatment Centre	Yaounde	Centre

Sponsors (2)

Lead Sponsor	Collaborator
Yaounde Central Hospital	CIHR Canadian HIV Trials Network

Country where clinical trial is conducted

Cameroon, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adherence	Measured using the Visual Analogue Scale, Self Report and Pharmacy Refill Data	Change from baseline at 6 months	No
Secondary	Weight		Change from baseline at 6 months	No
Secondary	Body Mass Index		Change from baseline at 6 months	No
Secondary	CDC classification		Change from baseline at 6 months	No
Secondary	WHO Classification		Change from baseline at 6 months	No
Secondary	Mortality	All cause mortality	6 months	No
Secondary	CD4 count		Change from baseline at 6 months	No
Secondary	Viral load		Change from baseline at 6 months	No
Secondary	Quality of life	Measured using the SF-12 quality of life form	Change from baseline at 6 months	No